Those aiming for above-average market returns often engage in the meticulous process of stock picking. Choosing the right stocks can make a substantial difference in your wealth.
After finishing at $0.89 in the prior trading day, Aprea Therapeutics Inc (NASDAQ: APRE) closed at $0.85, down -4.16%. In other words, the price has decreased by -$4.16 from its previous closing price. On the day, 0.15 million shares were traded. APRE stock price reached its highest trading level at $0.914 during the session, while it also had its lowest trading level at $0.8427.
Ratios:
Our goal is to gain a better understanding of APRE by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 5.20 and its Current Ratio is at 5.20. In the meantime, Its Debt-to-Equity ratio is 0.00 whereas as Long-Term Debt/Eq ratio is at 0.00.
On December 16, 2020, Berenberg started tracking the stock assigning a Buy rating and target price of $37.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Dec 10 ’25 when Duey Marc bought 21,459 shares for $1.17 per share. The transaction valued at 25,000 led to the insider holds 256,155 shares of the business.
Hamill John P. bought 5,000 shares of APRE for $5,825 on Dec 10 ’25. The SrVP/CFO/Prin Fin & Acct Ofcr now owns 27,733 shares after completing the transaction at $1.17 per share. On Apr 03 ’25, another insider, Gilad Oren, who serves as the President/CEO of the company, bought 5,500 shares for $1.84 each. As a result, the insider paid 10,110 and bolstered with 345,620 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, APRE now has a Market Capitalization of 5965743 and an Enterprise Value of -7607687. For the stock, the TTM Price-to-Sale (P/S) ratio is 12.17 while its Price-to-Book (P/B) ratio in mrq is 0.47. Its current Enterprise Value per Revenue stands at -15.582 whereas that against EBITDA is 0.551.
Stock Price History:
The Beta on a monthly basis for APRE is 1.43, which has changed by -0.7507003 over the last 52 weeks, in comparison to a change of 0.17511821 over the same period for the S&P500. Over the past 52 weeks, APRE has reached a high of $5.00, while it has fallen to a 52-week low of $0.88. The 50-Day Moving Average of the stock is -26.00%, while the 200-Day Moving Average is calculated to be -45.33%.
Shares Statistics:
The stock has traded on average 92.48K shares per day over the past 3-months and 43910 shares per day over the last 10 days, according to various share statistics. A total of 5.98M shares are outstanding, with a floating share count of 5.45M. Insiders hold about 22.14% of the company’s shares, while institutions hold 23.15% stake in the company. Shares short for APRE as of 1765756800 were 34578 with a Short Ratio of 0.37, compared to 1763078400 on 63277. Therefore, it implies a Short% of Shares Outstanding of 34578 and a Short% of Float of 0.5499999999999999.
Earnings Estimates
. The current rating of Aprea Therapeutics Inc (APRE) reflects the combined expertise of 1.0 analysts actively engaged in assessing its market performance.The consensus estimate for the next quarter is -$0.38, with high estimates of -$0.38 and low estimates of -$0.38. Analysts are recommending an EPS of between -$1.96 and -$1.96 for the fiscal current year, implying an average EPS of -$1.96. EPS for the following year is -$0.86, with 2.0 analysts recommending between -$0.51 and -$1.21.
Revenue Estimates
A total of 3 analysts have provided revenue estimates for APRE’s current fiscal year. The highest revenue estimate was $300k, while the lowest revenue estimate was $281k, resulting in an average revenue estimate of $287.33k. In the same quarter a year ago, actual revenue was $1.5M
